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Introduction 52
Regulatory T (Treg) cells actively suppress pathological and physiological 53 immune responses, thereby contributing to the maintenance of immunological self-54 tolerance and immune homeostasis. Their development occurs in the thymus as a 55 result of high-avidity TCR interactions with self-Ags (1), and are called thymus-56
derived Treg (tTreg) cells. These Treg cell subset are characterized by a stable 57 expression of the transcription factor forkhead box P3 (FoxP3) (2) and constitutive 58 high-level expression of CD25 (IL-2 receptor a chain) and thus denoted as 59
+ Treg cells. The severity of the autoimmune syndromes caused by 60 deficiencies in FoxP3 -scurfy in mice and IPEX in humans -highlights its central role 61
(reviewed in (3)). Treg cells also differentiate extrathymically from conventional T 62 cells and this differentiation is strongly modulated by cytokines such as IL-2 and 63
TGF-β (4-6). These Treg cells have been termed peripheral Treg (pTreg) and several 64
Ag-induced pTreg cell populations, with IL-10 based regulatory activity, appear to 65 have critical in vivo functions (7-9). Several experimental tolerogenic settings have 66 been shown to drive or increase expansion/differentiation of pTreg cells in vivo; these 67 include chronic activation and sub-immunogenic Ag presentation (10-12), exposure 68 to orally administered agonist peptides (13, 14) , lymphopenia-driven homeostatic 69 expansion (15-17) and use of small molecular weight compounds such as retinoic 70 acid and histone deacetylase inhibitors (18, 19) . 71
Alternative strategies to promote in vivo generation of stable pTreg cells use 72 the tolerogenic properties of immature dendritic cells (DCs). Indeed, DC-based 73 therapy has been proposed to restore tolerance in the context of several autoimmune 74 diseases (20) (21) (22) . The two main strategies developed are the direct targeting of 75 antigens to + steady state DCs (11, [23] [24] [25] [26] and the repetitive injection of 76 tolerogenic DCs (27) (28) (29) . We have previously demonstrated that repetitive injection of 77 immature and semi-mature DCs can prevent adverse clinical outcome and protect 78 mice from experimental collagen-induced arthritis (CIA) (30, 31) . This protection was 79 associated with the expansion of a particular FoxP3-negative CD4 + Treg cell 80 population characterized by the expression of CD49b (the alpha2 subunit of the 81 adhesion molecule VLA-2) which specifically binds to collagens I, II and X (30) . 82
These induced CD49b + Treg cells, which secrete high levels of IL-4 and IL-10, 83 displayed strong immunosuppressive properties in vivo, improving established CIA 84 and attenuating delayed type hypersensitivity reactions (32, 33) . Similarly, Benoist 85 and Mathis' group demonstrated that CD4 +
CD49b
+ Treg cells, present in naïve mice, 86
were more efficient in suppressing the onset of diabetes than CD4 + CD25
+ Treg cells 87 (34). As with the cell population we described, these cells' effect was IL-4 and IL-10 88 dependent. Recently, Gagliani et al. showed that CD49b and the lymphocyte 89 activation gene 3 (LAG-3) define the IL-10-producing FoxP3-negative T regulatory 90 type 1 cells (35) . 91
Altogether these data reveal a remarkable heterogeneity in pTreg cell 92 populations and define the CD49b molecule as a relevant marker for specific Treg 93 cell subsets. Interestingly, recent studies challenged the notion that FoxP3 94 expression is uniquely responsible for all aspects of the transcriptional signature of 95
+ Treg cells and showed that FoxP3-independent epigenetic changes are 96 required for Treg cell function (36, 37 
DC generation and injections 116
DCs were generated as previously described (30). Briefly, bone marrow cells were 117 harvested from the femur and tibiae of mice and washed in RPMI following red blood 118 cells lysis. T and B cells were depleted using mouse pan T and pan B Dynabeads® 119 (Dynal) and monocytes were removed by 4h plate adhesion. The remaining cells 120 were cultured in complete medium (RPMI 1640 supplemented with 5% FCS, 2mM L-121 glutamine, 5 x 10 -5 M b-mercaptoethanol, 100U/ml penicillin, 100 µg/ml streptomycin, 122 essential amino acids and 1 mM sodium pyruvate) with 1,000 IU/ml of rmGM-CSF 123 (R&D Systems) and 1,000 IU/ml of rmIL-4 (R&D Systems) at 5 x 10 5 cells/ml in 24-124 well plates. Culture medium was renewed at days 2 and 4. For in vivo experiments, 125
DCs were harvested at day 7. Syngeneic DBA/1, IL-10 KO or wild type littermates 126 were injected i.p. with 0.5 x 10 6 DCs in 100 µl PBS, 7, 5 and 3 days before 127 euthanasia for splenic T cell purification. 128
129
Antibodies and FACS analysis 130
Spleens were harvested and single-cell suspensions were obtained by gentle 131 passage through 70 μm nylon mesh filters (BD Biosciences). Following red blood 132 cells lysis using ACK buffer, suspensions were pre-blocked using purified anti-133 CD16/32 Ab (2.4.G2) for 10 min. For intracellular cytokine staining, cells were 134 stimulated during 48h at 37°C with anti-CD3/anti-CD28 antibody-coated Dynabeads 135 (Dynal Biotech ASA, Oslo, Norway). During the last 4 hours of stimulation, 50 ng/ml 136 of phorbol 12-myristate 13-acetate (PMA), 1 µg/ml of ionomycin and 10 µg/ml 137 brefeldin A (Sigma-Aldrich, Zwijndrecht, The Netherlands) was added. Subsequently, 138 cells were stained with surface antibodies (20 min, on ice). Cells were fixed using the 139 eBioscience permeabilization kit according to the manufacturer's procedure and 140 subsequently stained for intracellular markers. Data acquisition was performed on a 141
Canto II or LSR Fortessa flow cytometer (BD Biosciences, Mountain View, CA) and 142 analyses were performed using FlowJo software. 143
144
Treg cell isolation and adoptive cell transfer experiments 145
Splenocytes from DC-vaccinated mice were recovered by filtration on cell strainer, 146
washed and then CD4 + T cells purified by negative selection using Dynabeads. CD4 147 T cells were stained with anti-CD4, anti-CD49b and anti-CD25 conjugated antibodies 148 and cell sorting was performed on FACSAria (MRI platform Montpellier, Fig.S1 Data are presented as mean ± SEM and significance was determined using 214
GraphPad Prism software (GraphPad Software). Depending on the distribution of the 215 data, parametric or non-parametric tests with appropriate comparisons were used to 216 compare groups. A one-way or repeated two-way ANOVA with a post hoc multiple 217 comparison test were used when more than two groups were compared. 218
219
Results
220
DC-induced CD49b cells display an effector memory phenotype 221
As we previously published (30, 32) and as clearly shown in figure S1 , 222 + cells did not significantly change after 232 repeated DC injection, we observed a slight increase in the frequency of these cells 233 expressing FoxP3 (67 ± 1% to 76 ± 2%, p<0.0001). As shown in figure S1A 
cells. 303
To further characterize and compare the phenotypes of the DC-induced 304
CD49b
+ and CD25 + cells isolated from the same DC-vaccinated mice, we performed 305 6-10 colors cytometric analyses. We showed that, despite weakly expressing CD25 306 and the master regulator transcription factor FoxP3 (Fig. S1) KLRG1, CTLA-4, latency associated peptide (LAP) and glucocorticoid-induced TNFR 309 family related gene (GITR) (Fig. 3) . Interestingly, CD49b
+ cells also expressed 310 programmed cell death-1 (PD1), shown to play an important role in pTreg cell 311 induction and function (41), although at a lower level than that in CD25 + cells (Fig.  312   3A) . Moreover, expression of LAG-3, KLRG1 and CD103 molecules was in contrast 313 significantly higher in CD49b + than in CD25 + cells (Fig. 3A) . Within the CD49b + cell 314 population, we noted that LAG-3 expression was mostly restricted to the FoxP3 neg 315 cells, whereas KLRG1 and CD103 expressions were found in both FoxP3 + and 316
FoxP3 neg cells. 317
Several molecules sustaining the Treg cell suppressive function are known to 318 be highly expressed following activation. As CD25 and CD49b expressions are also 319 modulated following activation, we first purified the T cells from DC-vaccinated mice 320 by FACS-sorting them (Fig. S1 ) and the three resulting populations were analyzed 48 321 hours following in vitro stimulation. Phenotypic analysis of activated T cells clearly 322
showed that all T cells acquired CD25 expression, and that half of the CD25 + Treg 323 cells were FoxP3 + compared to less than 4% of the CD49b + Treg cells (Fig. 3B) . 324
Interestingly, compared to the CD25 + T cell population, that of the CD49b + T cells 325 displayed higher percentages or mean fluorescence intensity (MFI) of several 326 markers commonly expressed by Treg cells. These markers included Granzyme B 327 (GrB), GITR, inducible T-cell costimulator (ICOS), LAP and IL-10 in terms of 328 percentages, and CTLA-4 for MFI. We narrowed our focus down to effector 329 mechanisms by comparing the phenotype of IL-10 secreting T cells (gated within the 330
CD49b
+ cell population) with that of FoxP3 + cells (gated within the CD25 + cell 331 population) (Fig. S3) . Interestingly, the FoxP3 + cell sub-population displayed a higher 332 percentage of cells expressing LAP than did the IL-10 secreting sub-population (31 ± 333 8% versus 10 ± 0.5% respectively, p=0.008). Conversely, GITR (96 ± 0.5% versus 78 334 ± 3%, p= 0.026), CTLA-4 (97 ± 0.1% versus 84 ± 5%, p= 0.02) and GrB (31 ± 8% 335 versus 2.5 ± 0.3%, p=0.010) were more frequently expressed among the IL-10 336 secreting CD49b + Treg cells than in the FoxP3 + CD25 + cell sub-population. These 337 results suggest that, besides IL-10, these three molecules could play an important 338 role in the CD49b + suppressive function (Fig. S3) . 339 340
Peripherally induced CD49b
+ cells express Neuropilin-1 without co-expressing 341
Helios. 342
Neuropilin-1 (Nrp-1) was proposed as a Treg cell surface marker in 2004 (42) 343 and its coordinated expression along with Helios, an Ikaros family transcription factor, 344 was more recently suggested for use in distinguishing thymic derived from inducible 345
+ Treg cells (43-46). Indeed, pTreg cell populations generated in vivo 346 displayed reduced Nrp-1 expression compared with tTreg cells, indicating Nrp-1 as a 347 tTreg specific marker (26). As previously published for NOD and C57BL/6 mice (43), 348
we showed in DBA/1 mice that the majority of CD25 + cells express concurrently Nrp-349 1 and Helios (56 ± 3%) (Fig. 4) 
Peripheral induced CD49b cells express Th1-and Th2-specific transcriptional 358 factors and cytokines 359
Recent evidence suggests that the capacity of Treg cells to control polarized 360 settings can be associated with the expression of specific transcription factors, such 361 as T-bet, interferon regulatory factor 4 (IRF4) and STAT3 to control Th1, Th2 and 362
Th17 responses respectively (47-49). Treg cells expressing these transcription 363
factors can partially mimic the phenotype of the effector T cells, providing them with 364 particular homing, survival, or functional properties (50). It has been demonstrated 365 that 25% of FoxP3 + compared to only 5% of FoxP3 neg Treg cells isolated from spleen 366 express the canonical Th2 transcription factor Gata3 (51). These authors showed 367 that the expression of Gata3 controlled unbalanced polarization and inflammatory 368 cytokine production in Treg cells, and that it was required for the maintenance of 369
FoxP3 high level expression and promoted the accumulation of Treg cells at inflamed 370
sites (51). In our study in DBA/1 mice, we observed Gata3 expression in 8 ± 1% of 371 the CD25 + cells and in 47 ± 2% of the CD49b + cell population (Fig. 5A) . Furthermore, 372
we observed that only the DC-induced CD49b + cells displayed a considerable 373 proportion of double positive staining for T-bet and Gata3 (25 ± 1.5%), in contrast 374 with the CD4 + and CD25 + cells (2 ± 0.2% for both populations) (Fig. 5A, right panel) . 375
This DC-induced increase in the number of CD49b + cells expressing both T-bet and 376
Gata3 was statistically significant (25 ± 1.5% versus 2 ± 0.2%, p<0.0001). 377 C-Maf was the first Th2-specific transcription factor identified and has been 378 shown to play a critical role in trans-activating IL-4 and IL-10 expression during Th17 379 polarization. The ligand-activated transcription factor aryl hydrocarbon receptor 380 (AhR), like the proto-oncogene Maf, was shown to be strongly induced during Tr1 cell 381 differentiation with similarly high levels of expression found in both Tr1 and Th17 cells 382 (52). We thus evaluated the expression of c-Maf and AhR in CD49b + cells and found 383 them in 53 ± 2% and 82 ± 1% respectively, compared to in only 38 ± 1% and 39 ± 2% 384 respectively of the CD25 + population (Fig. 5B) . 385
To further characterize the cytokine secretion profile we quantified the level of 386 cytokine secretion in the supernatant of highly purified FACS-sorted cells following 387 their in vitro activation. Besides the high level of IL-10 secretion (19 ± 7 ng/ml), we 388 measured significantly elevated secretion levels of other type 2 cytokines, including 389 IL-4 (10 ± 2 ng/ml), IL-5 (18 ± 2 ng/ml) and IL-13 (31 ± 0.5 ng/ml), as well as a 390 relatively high amount of IFN-g (3 ± 1 ng/ml) in the supernatant of the CD49b + T cell 391 population. These results revealed an obvious type 2 dominant cytokine profile for 392 the CD49b + Treg cells and underscored their dissimilarity with Tr1 cells, which 393 secrete high levels of IL-10 without concomitant secretion of 53) . we performed robust statistical analyses using relative arthritic scores calculated 419 using the mean of the PBS-treated mice as 100% disease severity for each 420 experiment. We included in these experiments a control group of mice, which were 421 injected with the CD4 + cell population. As shown in figure 6C, figure 6D , injection of CD49b + isolated from wild-type 434 littermates significantly protected mice from arthritis whereas IL-10 deficient CD49b 
